MovDisordV3, PubMed, Corpus, bibRecord, 005013

Isoniazid therapy in Parkinson's disease.

Identifieur interne : 005013 ( PubMed/Corpus ); précédent : 005012; suivant : 005014

Isoniazid therapy in Parkinson's disease.

Auteurs : O S Gershanik ; M R Luquin ; O. Scipioni ; J A Obeso

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1988.

RBID : pubmed:3221901

English descriptors

KwdEn :
- Aged, Dyskinesia, Drug-Induced (cerebrospinal fluid), Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Humans, Isoniazid (cerebrospinal fluid), Isoniazid (pharmacokinetics), Isoniazid (therapeutic use), Levodopa (adverse effects), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy).
MESH :
- chemical , adverse effects : Levodopa.
- chemical , cerebrospinal fluid : Isoniazid.
- cerebrospinal fluid : Dyskinesia, Drug-Induced.
- complications : Parkinson Disease.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- chemical , pharmacokinetics : Isoniazid.
- chemical , therapeutic use : Isoniazid.
- Aged, Female, Humans, Male, Middle Aged.

Abstract

The effect of isoniazid on levodopa-induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. "Benefit of dose" choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.

DOI: 10.1002/mds.870030205
PubMed: 3221901

Links to Exploration step

pubmed:3221901

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Isoniazid therapy in Parkinson's disease.</title>
<author><name sortKey="Gershanik, O S" sort="Gershanik, O S" uniqKey="Gershanik O" first="O S" last="Gershanik">O S Gershanik</name>
<affiliation><nlm:affiliation>Centro Neurológico, Hospital Francés, Buenos Aires, Argentina.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name>
</author>
<author><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O" last="Scipioni">O. Scipioni</name>
</author>
<author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1988">1988</date>
<idno type="RBID">pubmed:3221901</idno>
<idno type="pmid">3221901</idno>
<idno type="doi">10.1002/mds.870030205</idno>
<idno type="wicri:Area/PubMed/Corpus">005013</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Isoniazid therapy in Parkinson's disease.</title>
<author><name sortKey="Gershanik, O S" sort="Gershanik, O S" uniqKey="Gershanik O" first="O S" last="Gershanik">O S Gershanik</name>
<affiliation><nlm:affiliation>Centro Neurológico, Hospital Francés, Buenos Aires, Argentina.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name>
</author>
<author><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O" last="Scipioni">O. Scipioni</name>
</author>
<author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1988" type="published">1988</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Dyskinesia, Drug-Induced (cerebrospinal fluid)</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Isoniazid (cerebrospinal fluid)</term>
<term>Isoniazid (pharmacokinetics)</term>
<term>Isoniazid (therapeutic use)</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Isoniazid</term>
</keywords>
<keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Isoniazid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Isoniazid</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The effect of isoniazid on levodopa-induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. "Benefit of dose" choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">3221901</PMID>
<DateCreated><Year>1989</Year>
<Month>03</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted><Year>1989</Year>
<Month>03</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>3</Volume>
<Issue>2</Issue>
<PubDate><Year>1988</Year>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Isoniazid therapy in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>133-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The effect of isoniazid on levodopa-induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. "Benefit of dose" choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gershanik</LastName>
<ForeName>O S</ForeName>
<Initials>OS</Initials>
<AffiliationInfo><Affiliation>Centro Neurológico, Hospital Francés, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Luquin</LastName>
<ForeName>M R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Scipioni</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Obeso</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V83O1VOZ8L</RegistryNumber>
<NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007538">Isoniazid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1988</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1988</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">3221901</ArticleId>
<ArticleId IdType="doi">10.1002/mds.870030205</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005013 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 005013 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:3221901
   |texte=   Isoniazid therapy in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:3221901" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Isoniazid therapy in Parkinson's disease.

Isoniazid therapy in Parkinson's disease.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki